BridgeBio CEO Neil Kumar at BIO22 (J.T. MacMillan Photography for Endpoints News)
January 18, 2024 11:27 AM EST
Financing

Bridge­Bio rais­es up to $1.2B, a month af­ter sub­mit­ting car­dio drug to FDA

Kyle LaHucik

Senior Reporter

Bridge­Bio has tapped in­vestors for up to $1.25 bil­lion as it pre­pares to com­mer­cial­ize its heart pill and get some breath­ing room to con­tin­ue run­ning …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

Eli Lil­ly sues the US gov­ern­ment over its pro­posed 340B re­bate mod­el

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times